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The chronic diseases of the airways and 
lungs, such as lung cancer, chronic 
obstructive pulmonary disease, tuberculosis, 
asthma, idiopathic pulmonary fibrosis, and 
pulmonary hypertension, impose enormous 
human suffering globally but their impact is 
far greater on developing countries and 
deprived population. These diseases will 
become one of the leading causes of death 
worldwide in the near future. (1) The rapid 
changes in life style, urbanization, and 
environmental degradation, smoking habit, 
increasing elderly population in developed 
countries etc., are all contributing toward the 
increase in patients with airway diseases. 
Current treatment strategies are strongly 
dependent on the type of malignancy and 
stage at the time of diagnosis but often 
involve a combination of surgery, 
chemotherapy, and/or radiation therapy. 
Biologically active phytochemicals present in 
plants and natural products, improve 
treatment efficiency in cancer patients and 
decrease adverse reactions. These 
phytochemicals having significant antitumor 
potential. 
In this review, we critically discuss the 
challenges and reasons behind limited clinical 
success of targeted delivery approaches in 
cancer treatment, in-spite of the huge number 
of published reports demonstrating their 
therapeutic potential in pre-clinical models. 
We also propose the focus areas for future 
research that will enable successful clinical 
translation of promising strategies for 
targeted delivery of cancer therapeutics. 
2. Nanoparticles and Cancer 
Nanoparticles constitute nano-sized 
carriers (5–200 nm) (2) whose variability and 
versatility can be seen in the wide range of 
applications that are being developed for 
them. The ability to control aspects such as 
shape, size, surface charge and composition at 
the atomic level, together with characteristics 
such as their biocompatibility or their ability 
to transport insoluble substances, makes them 
an excellent tool for the treatment of 
numerous diseases, including cancer. (3,4) 
Active targeting is one of the most promising 
applications for NPs, since they make it 
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possible to take advantage of the specific 
characteristics and specific profile of each 
tumor niche to direct treatments to it by 
functionalizing the NPs with antibodies, (5) 
tumor-specific antigens (TSA), microRNAs 
or siRNA, which, together with the properties 
of certain nanomaterials used in their 
synthesis, such as pH and/or temperature 
dependent degradation, response to light, 
magnetic or ultrasound stimuli, make it 
possible to release its load specifically at the 
tumor site, decreasing systemic toxicity 
enormously with respect to traditional 
treatment. (6,7) 
Currently, NPs have acquired a dual 
profile, being able to help in the diagnosis of 
disease in addition to granting targeted and 
specific therapy of disease (teragnosis). In 
addition, NPs could make it possible in the 
future to deliver personalized treatment for 
each patient, thus improving their response to 
treatment and their survival rate, striving 
towards achieving a complete cure. (8) 
3. Lipid-Based Nanocarriers 
Liposomes are the most studied delivery 
systems due to the biocompatibility and 
biodegradability that they present. The main 
components of these nanoparticles are 
phospholipids, which are organized in a 
bilayer structure due to their amphipathic 
properties. In presence of water, they form 
vesicles, improving the solubility and stability 
of anticancer drugs once they are loaded into 
their structure. (9) They are capable of 
encapsulating either hydrophobic or 
hydrophilic drugs. (10,11) In lung cancer 
treatment, liposomes may be a promising 
delivery system for drugs and genes. (12) The 
drug of choice for the treatment of NSCLC 
for the last two decades, cisplatin, is 
implicated in the development of 
nephrotoxicity in 20% of patients receiving 
high doses. (13) Table 1 lists current 
examples of liposomal formulations 
undergoing clinical trials intended for the 
treatment of cancer. In a recent report, 
researchers successfully loaded SLNs with 
Bcl-2 siRNA and paclitaxel for synergistic 
combination therapy as well as 
coencapsulated CdSe /ZnS quantum dots to 
bestow optical traceability. (14) Collectively, 
the properties of SLNs are ideally suited for 
combined chemo-and/ or gene-therapy and 
molecular imaging of cancer. 
Table 1. Lists current examples of liposomal formulations undergoing clinical trials 
Sr.No. Composition Indication Phase/Stage 
1 
Liposomal   
Cytarabine 
Central nervous system 
malignancies, 









Advanced cancer I/Completed 
4 Liposomal LE-SN38 Advanced cancer I/Completed 










Liposomal Entrapped Paclitaxel 
Easy to Use (LEP-ETU) 
Advanced cancer I/ Active 
 
4. Targeted Drug Delivery 
The whole idea targeted drugs go back to 
the year 1906 when Ehrlich (15) first 
suggested the ‘magic bullet’. The permanence 
of this idea is a strong sign of its appeal, but 
the ‘magic bullet’ is still a challenge to 
implement in the clinic. The problem is with 
three things; first thing is finding the target 
for a specific disease state; to find a drug that 
efficiently treats this disease; and discovering 
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an idea of taking the stable form of the drug 
while avoiding the immunogenic and 
nonspecific interactions that efficiently clear 
foreign material present in the body. (16) 
Targeted drug delivery includes giving 
medication to a patient in such a way that it 
enhances the amount of the medication in a 
few parts of the body in comparison to others. 
Targeted drug delivery includes concentrating 
the medication in the tissues of interest while 
decreasing the relative concentration of the 
medication in the other tissues. (17) The drug 
is administered in such a manner that the drug 
is only active in the targeted area of the body 
and then the drug is released over in a 
controlled manner e.g., colon targeted drug. 
This enhances efficacy and decreases side 
effects. It is very hard for a drug molecule to 
reach its endpoint in the complicated cellular 
network of an individual. Targeted delivery 
of drugs helps the drug molecule to reach 
preferably to the required region. The benefit 
of using this method includes a decrease in 
dose & side effect of the drug. (18) Research 
associated with the development of targeted 
drug delivery system is nowadays highly 
favored in the pharmaceutical field. (19,20) 
Active and passive targeting 
Passively targeted NCs, which rely solely 
on the EPR effect, may be insufficient to 
achieve efficient tumor targeting. We need 
more systematic studies to understand the 
interaction of NCs with physiological 
barriers, and the cues identified from those 
should be used to develop more sophisticated 
strategies. Active targeting strategies are 
much more complex than passive approaches. 
(21) In addition to the challenges associated 
with physiological barriers and tumor 
heterogeneity, a major challenge is posed by 
the complex design and engineering of these 
systems, which can complicate their 
pharmaceutical development and scale-up 
under good manufacturing practice (GMP) 
production and add significantly to the cost of 
the therapy. Additionally, for both passive 
and active targeting strategies, the 
development of companion diagnostic 
imaging technologies to evaluate the targeting 
efficiency of NCs is crucial. Pre-selection of 
suitable patients and tailoring treatments to 
specific patients will improve tumor 
accumulation, treatment efficacy, and 
therapeutic outcomes. (22) 
5. Challenges for Nanoparticle-Based Drug 
Delivery in Lung Cancer Therapy 
The past decade has witnessed tremendous 
growth and development of drug delivery 
technology utilizing nanoparticle systems. It 
is expected that the ongoing research efforts 
in nanomedicine will continue to lead towards 
safe, efficient, and feasible drug delivery and 
highly sensitive and improved imaging agents 
for diagnostic and disease monitoring 
applications. However, nanomedicine 
research is facing numerous challenges in 
bridging rapidly developing novel ideas and 
translating them into clinical practice. A 
number of obstacles including immune 
reaction, rate of clearance from circulation, 
efficiency in targeting, and ability to cross 
biological barriers will follow when these 
nanoparticle systems enter the preclinical and 
clinical testing arenas. (23) Having a solid 
understanding of the biological behavior of 
nanoparticles is imperative to achieve the 
highest drug delivery efficiency. Resident 
alveolar macrophages detect the presence of 
foreign particles, followed by engulfment via 
phagocytosis and finally digestion in 
lysosomal of macrophages. The 
bioavailability of anti-cancer drugs to cancer 
cells provides an indirect reflection of success 
rate of therapy. To achieve this, we should 
determine the key factors that affect the 
bioavailability of drug in lungs such as 
aqueous solubility, dissolution rate, efflux of 
drugs and drug clearance by alveolar 
macrophages. Table 2 outlines the factors 
involved in determining the bioavailability of 
drugs into tumor cells. 
Table 2. Outlines the factors involved in determining the bioavailability of drugs into tumor cells. 
Sr.No. Type of drugs 
The partition 
coefficient (log P) 
Water solubility 
1. Paclitaxel 3.50 Practically insoluble (24) 
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2. Docetaxel 4.10 Practically insoluble (25) 
3. Doxorubicin (HCl) 0.65 Soluble 
4. 5-Fluorouracil −0.89 Sparingly soluble (26) 
5. Celecoxib 3.68 Practically insoluble (27) 
6. Cisplatin −2.19 Soluble (28) 
 
Additionally, further consideration must be 
given to the complexity of nanoparticles and 
how this may have a negative impact on drug 
delivery. Multifunctional nanoparticles are 
hot topics in the field of nanomedicine. 
(29,30) A nanoparticle with a large number of 
surface functional groups provides an avenue 
for the attachment of multiple kinds of 
biomolecules for targeted drug delivery and 
diagnostic applications for lung cancer. A 
careful analysis of these nanoparticle systems, 
however, is necessary prior to testing in an in 
vivo system. 
6. Conclusion  
Nanoparticle-based medicine has infinite 
potential with novel applications continuously 
being developed for use in cancer diagnosis, 
detection, imaging, and treatment. These 
systems are already helping to address key 
issues with traditional anticancer agents such 
as nonspecific targeting, low therapeutic 
efficiencies, untoward side effects, and drug 
resistance as well as surpassing their 
predecessors with the ability to detect early 
metastasis. Many technical, pharmacological 
and service developments have been made in 
the staging and treatment of lung cancer over 
the past 10 years but questions still remain 
about how to best implement these and their 
cost effectiveness. Further research is needed 
to ascertain whether newer radiotherapy 
techniques, such as SABR, are equivalent to 
surgery for early stage lung cancers. Much 
discussion still surrounds the newer targeted 
agents’ cost effectiveness and whether 
improving early supportive care might be a 
good use of resources. 
Although new treatments are available 
there are inequalities in access to them and 
further consideration in commissioning of 
resources is needed to tackle the hub and 
spoke effect. Arguably the most effective 
development that has been made in improving 
the outcomes for lung cancer is CT screening; 
however, it still remains to be introduced in 
the UK despite good evidence for 
effectiveness. 
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